Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,271 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-104 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5.9
Industry P/E
--
EV/EBITDA
-17.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.2
Face value
--
Shares outstanding
47,755,900
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
DICE Therapeutics (DICE)
| 52.4 | 1.8 | 42.7 | 143.0 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
|---|---|
|
DICE Therapeutics (DICE)
| 23.3 |
|
S&P Small-Cap 600
| -17.4 |
|
BSE Sensex
| 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to... modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California. Read more
Founder, CEO & Director
Dr. J. Kevin Judice Ph.D.
Founder, CEO & Director
Dr. J. Kevin Judice Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of DICE Therapeutics Inc (DICE) is $47.55 (NASDAQ) as of 18-Aug-2023 09:30 EDT. DICE Therapeutics Inc (DICE) has given a return of 142.97% in the last 1 years.
Since, TTM earnings of DICE Therapeutics Inc (DICE) is negative, P/E ratio is not available.
The P/B ratio of DICE Therapeutics Inc (DICE) is 5.91 times as on 18-Aug-2023, a 50 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-17.36
|
-7.56
|
|
2021
|
-19.40
|
-9.07
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
-17.36
|
-7.56
|
The 52-week high and low of DICE Therapeutics Inc (DICE) are Rs -- and Rs -- as of 03-Apr-2026.
DICE Therapeutics Inc (DICE) has a market capitalisation of $ 2,271 Mln as on 18-Aug-2023. As per SEBI classification, it is a Small Cap company.
Before investing in DICE Therapeutics Inc (DICE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.